Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer
Abstract
Despite the impressive clinical response rate of osimertinib, a third-generation EGFR-TKI, as a frontline treatment for patients with EGFR-mutant non-small-cell lung cancer (NSCLC) or as a salvage therapy for patients with T790M mutation, resistance to osimertinib is common in the clinic. The mechanisms underlying osimertinib resistance are heterogenous. While genetic mutations within EGFR or other cancer driver pathways mediated mechanisms are well-documented, the role of tumor cell and tumor immune microenvironment in mediating the response to osimertinib remains elusive.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 16, 2023
- Source ID
- 10.3389/fimmu.2023.1077203
Entities
People
- Jean J. Zhao
- Qiwei Wang
- Tao Jiang
- Weihua Wang
- Ziying Lin
Organizations
- Cancer Research Institute
- National Institutes of Health
- The Breast Cancer Research Foundation
- United States Department of Defense